Rchr
J-GLOBAL ID：201301083890764880
Update date: Sep. 13, 2023
Shimojo Masahito
シモジョウ マサヒト | Shimojo Masahito
Affiliation and department：
Homepage URL (2)：
http://kaken.nii.ac.jp/d/r/90591925.ja.html
,
https://www.phs.osaka-u.ac.jp/en/research/researcherDetail.php?id=13
Research field (6)：
Molecular biology
, Medical biochemistry
, Pharmaceuticals - chemistry and drug development
, Respiratory medicine
, Tumor biology
, Neuroscience - general
Research keywords (20)：
神経内分泌がん
, 治療抵抗性がん
, Precision Medicine
, PM2.5
, breast cancer
, Splicing modifier
, Companion diagnostics, CDx
, miR-4516
, castration resistant prostate cancer (CRPC)
, prostate cancer
, SCLC
, alternative splicing
, SRRM4
, antisense oligonucleotide
, nucleic acid medicine
, iPSC
, epilepsy
, Prickle
, Huntington's Disease
, REST/NRSF
Research theme for competitive and other funds (13)：
- 2022 - 2025 Research on personalized medicine using miR-4516 and antisense oligonucleotide for treating refractory neuroendocrine cancer
- 2021 - 2022 小細胞肺がん治療に向けた分子標的核酸医薬開発
- 2017 - 2018 小細胞肺がん治療に向けた分子標的核酸医薬開発
- 2014 - 2016 Study of novel diagnostic tests and treatment of small cell lung cancer.
- 2015 - 小細胞肺がん治療を目的とした核酸医薬の探索
- 2012 - 2015 患者由来iPS細胞を用いる神経変性疾患の病態解明と治療戦略
- 2012 - 2014 Study of the neuron-specific alternative splicing in neuropathic pain
- 2012 - 2014 神経因性疼痛における神経選択的スプライシングを標的とした発症機序解明
- 2006 - 2010 Studies of novel REST/NRSF-Interacting LIM domain Protein (RILP) in Huntington’s Disease
- 2009 - 2010 Studies of novel REST/NRSF-Interacting LIM domain Protein (RILP) in Huntington’s disease.
- 2006 - 2009 Studies of novel REST/NRSF-Interacting LIM domain Protein (RILP) in Huntington’s disease.
- 2003 - 2007 Study of novel REST/NRSF-Interacting LIM domain Protein
- 2003 - 2007 Study of Novel REST/NRSF-Interacting LIM domain Protein.
Show all
Papers (25)：
-
Misa Yoshida, Chihiro Oda, Keishiro Mishima, Itsuki Tsuji, Satoshi Obika, Masahito Shimojo. An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells. Cancer cell international. 2023. 23. 1. 8-8
-
Shimojo M, Kasahara Y, Inoue M, Tsunoda SI, Shudo Y, Kurata T, Obika S. A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer. Scientific reports. 2019. 9. 1. 7618-7618
-
Yoshie Shudo, Masahito Shimojo, Mikihiko Fukunaga, Seiji Ito. Pituitary adenylate cyclase-activating polypeptide is regulated by alternative splicing of transcriptional repressor REST/NRSF in nerve injury. LIFE SCIENCES. 2015. 143. 174-181
-
Jingshan Lu, Ikuko Yao, Masahito Shimojo, Tayo Katano, Hitoshi Uchida, Mitsutoshi Setou, Seiji Ito. Identification of nitrated tyrosine residues of protein kinase G-I alpha by mass spectrometry. ANALYTICAL AND BIOANALYTICAL CHEMISTRY. 2014. 406. 5. 1387-1396
-
Masahito Shimojo, Yoshie Shudo, Masatoshi Ikeda, Tomoyo Kobashi, Seiji Ito. The small cell lung cancer-specific isoform of RE1-silencing transcription factor (REST) is regulated by neural-specific Ser/Arg repeat-related protein of 100 kDa (nSR100). Molecular Cancer Research. 2013. 11. 10. 1258-1268
ｍore...
MISC (3)：
Patents (5)：
-
Antisense oligonucleotide for controlling REST expression
-
細胞内への核酸分子取り込み促進剤、医薬組成物、及び新規化合物
-
小細胞肺がんの診断薬及び治療薬
-
オリゴヌクレオチドを含有する小細胞肺癌治療薬
-
REST mRNA前駆体のプロセシングにおけるNエキソンのスキッピングを誘導するオリゴヌクレオチド
Books (3)：
-
Encyclopedia of Cancer Chapter Title: RE1-Silencing Transcription Factor Edited by Dr. Manfred Schwab
Springer 2017
-
痛みの可塑性と慢性化 特集痛みとしびれのサイエンス-基礎と臨床
脊椎脊髄ジャーナル 2011
-
Chapter 20 - Regulation of cholinergic gene expression by NRSF/REST Cholinergic Mechanisms: Function and Dysfunction
CRC Press 2004 ISBN:1841840750
Lectures and oral presentations (25)：
-
小細胞肺がん治療を目的としたアンチセンス核酸SRRM4-ASOの体内動態について
(日本薬学会第143年会 2023)
-
アンチセンス活性向上を目的としたgapmer型アンチセンス核酸のデザイン戦略
(日本薬学会第143年会 2023)
-
TRPC3/C6チャネル活性化剤を用いたアンチセンス核酸の細胞内取り込みに関する研究
(日本薬学会第143年会 2023)
-
悪性脳腫瘍治療を志向した転写因子RESTに対するギャップマー型アンチセンス核酸の開発
(日本薬学会第143年会 2023)
-
Development of splice-switching oligonucleotides (SSOs) that control the tumor suppressor REST
(18th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) 2022)
ｍore...
Education (4)：
- 1992 - 1995 Nagasaki University Graduate School of Pharmaceutical Sciences
- 1990 - 1992 Nagasaki University Graduate School of Pharmaceutical Sciences
- 1986 - 1990 Nagasaki University Pharmaceutical Sciences
- 1986 - 1990 Nagasaki University School of Pharmaceutical Sciences
Professional career (1)：
Work history (6)：
Committee career (4)：
- 2014/10 - 現在 Austin Journal of Cancer and Clinical Research
- 2014/09 - 現在 Austin Journal of Lung Cancer Research Editorial Board
- 2014/09 - 2016/03 Edorium Journal of Biochemistry Editor-in-Chief
- 2012 - 2016/03 Scientifica Editorial Board
Awards (1)：
- 2020/04 - Public Interest Incorporated Foundation Kiyoko Goto and Paul Bourdarie Cancer Foundation The 8th Kiyoko and Paul Bourdarie-Goto Scientific Prize A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer (Scientific Reports volume 9, Article number: 7618 (2019))
Association Membership(s) (4)：
Japanese Cancer Association
, THE MOLECULAR BIOLOGY SOCIETY OF JAPAN
, American Society for Biochemistry & Molecular Biology
, Society for Neuroscience
